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Abstract 
Background: Type 2 diabetes mellitus (T2DM) has gained pandemic proportions becoming a global threat within 
the last few decades. In parallel to the increasing prevalence, healthcare costs have become a huge economic burden 
for the hospital and governments. Bariatric surgery has been proven to induce glycemic control in obese type 2 dia-
betics. However, the cost effectiveness of metabolic surgery in overweight, obese and morbidly obese individuals has 
not been documented. We aimed to demonstrate the efficacy and reduced diabetic-medication cost after diverted 
sleeve gastrectomy with ileal interposition (DSIT) in type 2 diabetic individuals followed more than 1 year.
Methods: Records of 116 type 2 diabetic patients operated by DSIT at a dedicated metabolic surgery clinic between 
October 2011 and April 2013 were retrospectively reviewed. A comparison was made between the annual diabetic 
medication cost before and after surgery using the paired t test. The alterations in BMI and HbA1c were recorded and 
analyzed.
Results: Diverted sleeve gastrectomy with ileal interposition led to a marked reduction in BMI and improved gly-
cemic control after 1 year follow-up. Mean HbA1c levels decreased from a mean of 8.9 ± 1.7 to 6.6 ± 1.1 1 year after 
surgery (p < 0.001). Mean preoperative BMI declined from 32.9 ± 4.3  to 24.7 ± 2.7 kg/m2 (p < 0.001). Cost of diabetic 
medication decreased from a mean 660.08 USD/year to 65.12 USD 1 year after surgery (p < 0.001).
Conclusion: Our results have shown that DSIT operation leads to a significantly better glycemic control and lower 
diabetic medication costs at 1 year.
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Background
Metabolic Syndrome and especially type 2 diabetes melli-
tus (T2DM) became a global problem during recent dec-
ades. Its prevalence reached 8.3 % among adults and its 
estimated prevalence for 2030 will be 10.1 %, showing a 
22  % increase (Buckley et  al. 2012). According to Inter-
national Diabetes Foundation (IDF) 2013 reports, Turkey 
has the highest prevalence of diabetes in Europe with 
14.8 % of adults (International Diabetes Federation 2013). 
In parallel to this increasing prevalence, co-morbidities 
and treatment costs display a notable increase and yield 
a huge economic burden for insurance systems (Bren-
nan et al. 2014). The IDF estimated that diabetes would 
cost the Turkish health care system 6.5b USD per year 
by 2030. This estimate has already been reached by 2010. 
The 2013 report indicates an annual diabetes related cost 
of 866 USD per patient (International Diabetes Federa-
tion 2013; Brennan et al. 2014; Malhan 2011; Malhan and 
Vlachopioti 2011).
According to national database registry of Turkey, type 
2 diabetic patients constitute 95  % of all diabetics and 
the annual total cost of type 2 diabetes is 5.14 billion 
Euros. The majority of this amount is utilized for com-
plications, whereby drug costs constitute only 10.5 % of 
the total expenses in type 2 diabetic patients (Malhan 
and Vlachopioti 2011). However, with the progression of 
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the disease, drug usage (esp. insulin) increase and none 
of the currently available medications provide a solution 
for the continuing progressive beta cell failure (DeP-
aula et al. 2009). Obesity surgery have shown promising 
and superior results with respect to metabolic control, 
weight control and the need for medications, by creating 
a reduced insulin demand and increased insulin activity 
(Sjöström et al. 2014; Halperin et al. 2014; Aminian et al. 
2014; Rubino et al. 2009; Ghiassi et al. 2012; Chiapaikeo 
et al. 2014).
Currently, the most widespread procedures in obesity 
surgery are gastric bypass and sleeve gastrectomy. Unfor-
tunately, the third most widespread procedures in terms 
of frequency are revision operations. Sadly, the word 
“revision” represents the disability and inefficiency of the 
operations performed. Just like any other field in surgery, 
obesity surgery also has a learning curve of its own and 
it is obvious that the reason of insufficient weight loss/
weight regain problems occurring within the first year 
after surgery is technical incompetency. However, long-
term follow-up results of the patients who have under-
gone gastric banding or sleeve gastrectomy prove that 
the main problem reveals itself 5 years after surgery and 
one-third of those patients require revision or additional 
surgical intervention (Chiapaikeo et al. 2014).
Diverted sleeve gastrectomy with ileal transposition 
(DSIT) consists of a gastric sleeve or fundectomy together 
with duodenal diversion and interposition of a long seg-
ment of ileum between the first centimeters of duodenum 
and 50th cm of jejunum. This operation has been shown 
to be safe and effective especially for obese and over-
weight patients with T2DM (DePaula et al. 2009).
The aim of the present study was to demonstrate the 
efficacy and reduced diabetic-medication cost after DSIT 
in type 2 diabetic individuals.
Methods
Study design
We retrospectively analyzed the prospectively collected 
data of 206 type 2 diabetic patients operated at a “Center 
of Excellence in Bariatric and Metabolic Surgery” at Tak-
sim German Hospital between October 2011 and April 
2013. All patients underwent the same surgical procedure 
(DSIT) carried out by the same surgical team. Of the 206 
patients, 116 cases with complete 1-year postoperative 
follow up were enrolled in the study. Institutional Ethical 
Committee approval was obtained before the study was 
set up (14.11.2011-#11-07).
Inclusion criteria were at least 3  years duration of 
T2DM under stable medical treatment, HbA1c >7 % for 
more than 3 months, weight stability, defined as no sig-
nificant change (>3 %) within the last 3 months and BMI 
>25 kg/m2. Patients were excluded if they had a fasting C 
peptide level <0.5 ng/ml or Anti GAD (Glutamic Adeno-
sine De-carboxylase) Antibody positivity. Other exclu-
sion criteria were previous major abdominal surgery, 
pregnancy, severe eating disorders and usage of medica-
tions for eating disorders.
Surgical procedure
All patients underwent the laparoscopic DSIT operation, 
as previously described (Celik et al. 2014). Briefly, we start 
with a sleeve gastrectomy or fundectomy (depending on 
the BMI) and progress with duodenal transection 2–3 cm 
from the pylorus. This decision was based on patients’ 
BMI. Fundectomy was performed, leaving all antrum 
intact, in patients with BMI 25–30 kg/m2. Sleeve gastrec-
tomy with 40F calibration plug was performed in patients 
with BMI 30–35 kg/m2. Sleeve gastrectomy with 34F cali-
bration plug was performed in patients with BMI >35 kg/
m2. The main rational for individual applications was not 
to cause weight loss more than expected due to excessive 
mechanical restriction. The sleeved stomach is trans-
ferred to the lower abdomen through a transverse meso-
colic opening. The last 30 cm of ileum is preserved and 
a 170  cm segment of distal ileal segment is interposed 
in between the duodenal end of the stomach and 50 cm 
from the Treitz ligament. Ileal ends are anastomosed 
to each other and all the mesenteric defects are closed 
one by one using 3/0 polypropylene (Fig. 1). All patients 
received routine multivitamin supplements for at least 
6 months after surgery.
Outcome parameters
All drug names and their doses were obtained from the 
BOLD (Bariatric Outcomes Longitudinal Database) sys-
tem and transferred to create Excel files. The change in 
BMI and HbA1c were also recorded and analyzed. The 
drug costs were obtained from national social insur-
ance system database and listed. Drug doses and the 
total daily usage was documented; costing on a daily and 
annual basis was evaluated accordingly. The costs have 
been measured in Turkish Liras (TL) and transferred to 
United States Dollars (USD) based on currency exchange 
rate of Turkish Central Bank on April 24, 2015. One 
USD = 2.7174 TL, http://www.tcmb.gov.tr).
Statistical analysis
All data was transferred to IBM Statistical Package for 
Social Sciences (SPSS) Statistics 21.0 program for anal-
ysis (SPSS Inc., Chicago, IL, USA). The change in all 
dependent parameters between preoperative and postop-
erative 1st year was analyzed using paired t test. Statisti-
cal significance was set at p < 0.05.
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Results
The group of patients consisted of 79 males and 37 
females with a mean age of 54.2  ±  8.7 (range 24–77) 
and a mean diabetic duration of 13.3 ± 5.7 (range 3–35) 
years. Mean preoperative BMI was 32.9  ±  4.7 (range 
25.4–50.2) kg/m2 and mean postoperative BMI was 
24.7 ± 2.7 (range 19.1–33.6) kg/m2. Mean change in BMI 
was 8.1 (range 0.7–19.2) kg/m2 and percentage of excess 
BMI loss (EBMIL) was 72.4 %. Mean weight loss at 1 year 
was 24.3 ± 8.1 (range −2.7 to 40.4) kg.
Mean preoperative HbA1c was 8.9  ±  1.7 which 
dropped down to 6.6  ±  1.1 1  year after surgery 
(p  <  0.001). Of those, 38 patients (32.8  %) experienced 
a complete remission (HbA1c <6  %), and 30 patients 
(25.9 %) had a partial remission (HbA1c = 6–6.5 %).
Postoperatively, 26 patients (22.4  %) had an HbA1c 
between 6.5 and 7.5 % (2 of them were on oral antidia-
betics) and 22 patients (19 %) had a 1 year HbA1c above 
7.5 %. Among these 22 patients, 20 were on combination 
oral antidiabetics (OAD), and 2 were using OAD plus 
single dose of long acting insulin. By the end of 1-year fol-
low up, 58.7 % of patients were under remission (32.8 % 
complete remission, and 25.9 % partial remission) with-
out medication. 81.0  % of patients had a mean HbA1c 
below 7.5 %. Twenty-two patients (19 %) had an HbA1c 
above 7.5 %; all of whom were on insulin preoperatively, 
with a mean HbA1c of 9.9 ±  1.9. Mean HbA1c, of this 
group at 1 year was 8.5 ± 0.8 (p = 0.002).
It is of particular interest to note that a total 99 patients 
(83.2  %) were either on insulin only or combination of 
OAD with insulin preoperatively, which shows the severity 
of disease burden in the patient population. Preoperatively, 
17 cases were on OAD, 16 were on insulin only and 83 were 
on insulin plus OAD. In total, 3 of 17 (17.6 %) on OAD, 3 
of the 16 (18.75 %) on insulin and 16 of the 83 (19.27 %) on 
insulin + OAD required OAD treatment 1 year after sur-
gery. Postoperatively, 21 % of the patients required antidia-
betic treatment 1 year after surgery (Table 1).
Preoperatively, the mean cost of anti-diabetic medi-
cations was 660.08  ±  426.05 USD, which decreased to 
Fig. 1 Schematic demonstration of the operation. a Sleeve gastrectomy. b Duodenal transection. c Inframesocolic transfer of the sleeve. d Interpo-
sition of the ileal segment between distal stomach and the proximal jejunum.
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65.12  ±  138.23 USD 1  year postoperatively (p  <  0.001) 
(Table 2).
Discussion
According to the International Diabetes Federation (IDF) 
report in 2013, estimated global mortality of diabetes 
is 5.1 million people which results in an expense of 548 
billion USD (International Diabetes Federation 2013). 
Majority of these expenses are related to co-morbidities 
treatment rather than drug costs (Malhan and Vlacho-
pioti 2011).
To the best of our knowledge, the present study is the 
first to analyze the effects of DSIT operation on diabe-
tes related medication costs. Our data clearly demon-
strate that surgery revealed more than 90 % reduction in 
the costs of anti-diabetic medications (660.08 vs. 65.12 
USD, p  <  0.001). Apart from costs of medication, other 
disease related costs such as treatment and follow-up 
of co-morbidities, doctor visits, blood tests and glucose 
measurements have not been analyzed in the present 
paper and may be the further investigated in other stud-
ies. We think that analysis of other disease related costs 
may indicate an obvious beneficial effect of surgery in all 
these parameters.
Within the last few decades, reports of surgical treat-
ment have demonstrated significant benefits on T2DM 
and other components of metabolic syndrome (Buckley 
et  al. 2012). However, majority of the reports belong to 
surgery performed on morbidly obese patients. Diverted 
sleeve gastrectomy with ileal transposition is a novel 
technique that has been shown to be safe and effective 
even in type 2 diabetic subjects with low BMI (Kumar 
et al. 2009; Kota et al. 2012). Other reports of DSIT per-
formed on non-morbidly obese type 2 diabetic patients 
with a mean 39.1 (25–61) months follow up confirmed 
the beneficial effects and marked remission in diabetes, 
weight control, hypertension and dyslipidemia (DePaula 
et al. 2012). These effects have been documented in other 
publications and its effects on lipid metabolism have 
been particularly associated with the change in bilio-
enteric circulation (Yang et al. 2013; DePaula et al. 2010). 
Similarly, beneficial effects on glycemia have been attrib-
uted to the improvement in insulin sensitivity and beta 
cell function confirmed by prospective studies (Vencio 
et al. 2011). Other reports of short term (18 months) fol-
low up of non-morbidly obese patients treated by DSIT 
yielded 80 % remission in T2DM along with appropriate 
weight control without significant nutritional deficien-
cies. However, 20  % of patients still required treatment 
with OAD (Tinoco et al. 2011).
Diverted sleeve gastrectomy with ileal transposi-
tion technique is not associated with uncontrollable or 
severe weight loss. Postoperative weight loss is propor-
tionate with preoperative severity of obesity. According 
to a study by De Paula et al. normal weight, overweight 
and obese patients treated by DSIT have lost a mean of 
9.4, 16.8 and 23.2 kg, respectively. Irrespective of weight 
loss, all groups presented marked improvements in insu-
lin output, insulin sensitivity and beta cell function (De 
Paula et al. 2011a, b).
All the cited articles in this manuscript indicate the 
efficacy of DSIT operation in controlling all the param-
eters linked with metabolic syndrome in a wide BMI 
range. Diverted sleeve gastrectomy with ileal transposi-
tion provides high rates of remission for all co-morbid-
ities not only in morbidly obese individuals, but also in 
normal weight, overweight and obese patients. In the 
present paper, all patients were either overweight or mor-
bid obese and there were not any patients with normal 
weight. Mean HbA1c dropped from a mean of 8.9 ± 1.7 
Table 1 Patients pre- and postoperative antidiabetic medication requirement
OAD oral antidiabetics.
Preoperative drugs Postoperative drug use
None (n = 92) Only OAD (n = 22) OAD + insulin (n = 2) Total (n = 116)
n (%) n (%) n (%)
Only OAD (n = 17), n (%) 14 (82 %) 3 (18 %) 0 (0 %) (100 %)
Only insulin (n = 16), n (%) 13 (81 %) 3 (19 %) 0 (0 %) (100 %)
OAD + insulin (n = 83), n (%) 65 (78 %) 16 (19 %) 2 (2 %) (100 %)
Total (n = 116), n (%) 92 (79 %) 22 (19 %) 2 (2 %) (100 %)
Table 2 Mean anti-diabetic medication costs in the preop-
erative and postoperative 1 year follow-up
USD United States dollars, SD standard deviation.
Annual drug expenses  
(USD) (n = 116), mean ± SD
T p value
Preoperative 660.08 ± 426.05 14.877 <0.001
Postoperative 1 year 65.12 ± 138.23
Difference in expenses 594.96 ± 430.74
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to 6.6  ±  1.1 1  year after surgery. According to Turkish 
Ministry of Health Diabetes Prevention and Control Pro-
gram, the targeted level of HbA1c should be below 6.5 % 
(Ministry of Health of Turkey: Turkey diabetes preven-
tion and control program 2011). In our study, 58.7 % of 
our patients have achieved an HbA1c below 6.5% and 
81 % of the whole patient group reached an HbA1c below 
7.5 %. Only two of these patients were still on OAD, while 
79 % of our patients gave up all anti-diabetic medications. 
Similar to our results, recent publications indicate that 
surgical modalities offer a more effective mode of treat-
ment for correction of metabolic parameters in T2DM 
(Cotugno et al. 2015; Schauer et al. 2012).
The main limitation of our study include the retrospec-
tive design. Secondly, some details of history and factors 
that may influence the outcome may not be completely 
documented. For example, we did not take into account 
the cost of surgery, hospital stay, clinical follow-up of the 
surgical group (consultations, exams, hospitalizations), 
complications, safety of the procedure and the nutritional 
supplements that these patients should take for life. 
Thirdly, the present population may not be comparable to 
the more obese population. Finally, follow-up could only 
maintained in 56 % of the cases. The low follow-up rate 
may be due to the low socioeconomic condition, trans-
portation difficulties and tendency of the patients not to 
return for follow-up once their symptoms are relieved. 
Due to these restrictions, associations should be inter-
preted with caution.
In conclusion, DSIT operation can provide lower dia-
betic medication costs at 1  year. Moreover, an effective 
weight control in a wide BMI range can be achieved. 
However, further prospective controlled trials are war-
ranted to confirm these results.
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